Robust Revenue Growth, Sharp Margin Expansion and Increased Capex Plans Reinforce Long-Term Growth Story; Brokerages Remain Bullish

Shares of Laurus Labs climbed to a fresh lifetime high on Monday after the pharmaceutical company reported a record-breaking financial performance for the first quarter of FY27. Strong growth across its Contract Development and Manufacturing Organisation (CDMO) business, improving profitability and a higher capital expenditure roadmap fuelled investor optimism, pushing the stock to ₹1,662.45 during intraday trade.

The stock has emerged as one of the best-performing pharmaceutical counters on Dalal Street, gaining around 55% in the last five months, while the benchmark BSE Sensex declined nearly 6% over the same period. Over the last 14 months, Laurus Labs has generated an impressive return of nearly 176%, highlighting the market's growing confidence in the company's transformation into a global pharmaceutical manufacturing partner.

The latest quarterly performance further strengthens the company's position as one of India's fastest-growing pharmaceutical exporters and CDMO players.

Record Quarterly Revenue Reflects Strong Business Momentum

Laurus Labs reported its highest-ever quarterly revenue, driven by robust demand across its CDMO operations and Affordable Medicines business.

Q1 FY27 Financial Highlights

The company's operating performance exceeded market expectations, with EBITDA growing much faster than revenue due to improved capacity utilisation, favourable product mix and stronger operating leverage.

Gross margins also strengthened considerably, reflecting higher contribution from value-added businesses and better commercial execution.

CDMO Business Continues to Drive Growth

The biggest contributor to Laurus Labs' recent success has been its rapidly expanding Contract Development and Manufacturing Organisation (CDMO) business.

Management stated that increasing commercial deliveries for global pharmaceutical companies and higher contributions from late-stage clinical programmes significantly boosted quarterly earnings.

Over the past two years, the quarterly revenue run rate of the CDMO division has increased dramatically—from approximately ₹220–250 crore to nearly ₹800 crore, demonstrating the success of the company's strategic shift towards high-value pharmaceutical outsourcing.

As more clinical-stage products receive regulatory approvals, management expects a larger proportion of CDMO revenues to transition into long-term commercial manufacturing contracts.

Affordable Medicines Segment Maintains Strong Performance

Alongside CDMO, Laurus Labs' Affordable Medicines business continued to deliver healthy growth despite macroeconomic uncertainties across global markets.

The segment benefited from:

• Strong demand for generic medicines.

• Improved product mix.

• Better pricing realisations.

• Efficient manufacturing operations.

• Expansion into new international markets.

The balanced contribution from both CDMO and generic pharmaceuticals has helped diversify the company's revenue base while improving earnings stability.

Higher Capital Expenditure Signals Management Confidence

In a significant announcement, Laurus Labs raised its FY27 capital expenditure guidance to ₹2,000 crore, up from the earlier estimate of ₹1,500 crore.

The additional investment will primarily support:

• Expansion of Active Pharmaceutical Ingredient (API) manufacturing.

• Intermediate production facilities.

• Human healthcare programmes.

• Animal healthcare projects.

• New manufacturing technologies.

• Capacity expansion for rising customer demand.

The increase in planned investments reflects management's confidence in sustained demand from global pharmaceutical companies.

Investments in Biologics and ADCs Open New Growth Avenues

Laurus Labs continues to strengthen its presence in high-value pharmaceutical technologies.

During the quarter, the company announced:

• Agreements to in-license two Antibody Drug Conjugate (ADC) programmes.

• Expansion of biologics manufacturing capabilities.

• Investments in integrated pharmaceutical development platforms.

• Continued focus on differentiated technologies.

These initiatives are expected to diversify the company's revenue streams while positioning Laurus Labs in some of the fastest-growing segments of the global pharmaceutical industry.

Commercial Fermentation Facility to Become Next Growth Driver

The company confirmed that construction of its large-scale commercial fermentation facility remains on schedule.

The project includes:

• More than 400 KL commercial fermentation capacity.

• Expanded downstream processing infrastructure.

• Commercial commissioning targeted by the end of calendar year 2026.

Management expects precision fermentation to become a meaningful contributor to revenue over the next 12 to 18 months as multiple customer programmes move into commercial production.

Commercialisation Pipeline Continues to Expand

Nearly 45% of Laurus Labs' CDMO business currently comes from projects that are still in the clinical development phase.

As these programmes receive regulatory approvals, they are expected to transition into large-scale commercial manufacturing.

Management highlighted that one important product has already secured global regulatory approval, enabling the company to begin commercial production and strengthening long-term revenue visibility.

This growing pipeline provides significant earnings potential over the coming years.

Brokerages Raise Target Prices After Earnings Beat

Following the strong quarterly performance, leading brokerage firms reiterated their positive outlook on Laurus Labs.

Motilal Oswal Financial Services

Motilal Oswal maintained its 'Buy' recommendation with a target price of ₹1,980.

According to the brokerage:

• CDMO growth remains exceptionally strong.

• Capacity expansion is backed by confirmed customer demand.

• Investments in biologics and ADCs strengthen the long-term opportunity.

• The company is expected to deliver an earnings CAGR of around 24% between FY26 and FY28.

ICICI Securities

ICICI Securities also retained its 'Buy' recommendation while assigning a target price of ₹1,890.

The brokerage believes Laurus Labs deserves premium valuations because of:

• Consistent operational execution.

• Aggressive capacity expansion.

• Strong earnings visibility.

• Long-term strategic investments.

• Successful monetisation of previous capital expenditure.

According to ICICI Securities, Laurus Labs has consistently demonstrated its ability to convert investments into profitable growth over time.

Laurus Pharma Zone to Anchor Future Expansion

Another major long-term growth catalyst is the company's ambitious Laurus Pharma Zone (LPZ) project in Andhra Pradesh.

The project spans approximately 530 acres and is expected to involve investments of nearly ₹5,630 crore over three development phases across the next eight years.

The integrated manufacturing hub will support:

• API production.

• CDMO manufacturing.

• Biologics.

• Specialty pharmaceuticals.

• Export-oriented manufacturing.

• Advanced pharmaceutical technologies.

Once fully operational, LPZ is expected to significantly enhance Laurus Labs' manufacturing capacity and strengthen its global competitiveness.

Key Reasons Behind the Stock Rally

Investors responded positively to multiple favourable developments.

Major Positive Triggers

• Record quarterly revenue.

• Strong EBITDA growth.

• Margin expansion above 31%.

• Rapid CDMO business growth.

• Increased capital expenditure guidance.

• Expansion into biologics and ADCs.

• Large commercial manufacturing pipeline.

• Positive brokerage recommendations.

• Strong long-term earnings visibility.

Together, these factors reinforce the company's transition from a traditional generic drug manufacturer into a diversified global pharmaceutical solutions provider.

Risks Investors Should Watch

Despite the encouraging outlook, investors should continue monitoring several important variables.

These include:

• Timely commissioning of new manufacturing facilities.

• Regulatory approvals for CDMO projects.

• Global pharmaceutical demand.

• Execution of higher capital expenditure.

• Pricing pressure in generic medicines.

• Foreign exchange movements.

• Client concentration.

• Raw material cost inflation.

The company's ability to execute these large-scale investments efficiently will play a critical role in sustaining future earnings growth.